Docetaxel liposomal (Sun Pharma Advanced Research Company)

多西他赛脂质体

Report date: 2022/07/04 19:38:02

Base Information

Drug NameDocetaxel liposomal (Sun Pharma Advanced Research Company)
Drug Alias NameDocetaxel injection concentrate for nanodispersionDocetaxel nanodispersionLiposome-encapsulated docetaxelDICN
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitorsTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungHypopharyngeal NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSun Pharmaceutical Industries Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChangzhou Jinyuan Pharmaceutical Manufacturing Co LtdSun Yat-Sen UniversityChangzhou Pacific Pharmaceutical Research Institute Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungHypopharyngeal NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG